ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
Rubrics: HEMATOLOGY
Authors:
1.
N.A. Semashko Republic Clinical Hospital
(Haematologist)
Ulan-Ude, Ulan-Ude, Russian Federation
Ulan-Ude, Ulan-Ude, Russian Federation
2.
N.A. Semashko Republic Clinical Hospital
(Haematology Department, Head)
Ulan-Ude, Ulan-Ude, Russian Federation
Ulan-Ude, Ulan-Ude, Russian Federation
3.
N.A. Semashko Republic Clinical Hospital
(Cardiologist)
Ulan-Ude, Ulan-Ude, Russian Federation
Ulan-Ude, Ulan-Ude, Russian Federation
4.
N.A. Semashko Republic Clinical Hospital
(Haematologist)
Ulan-Ude, Ulan-Ude, Russian Federation
Ulan-Ude, Ulan-Ude, Russian Federation
Type:
Article
Pages:
from 39
to 42
Status:
Published
Received:
23.10.2017
Accepted:
02.11.2017
Published:
02.11.2017
Subject area:
UDK 61 Медицина. Охрана здоровья
Language:
Russian
Keywords:
pervichnyy mielofibroz, mutaciya-JAK2, hMPZ, targetnaya terapiya
Abstract (English):
Aktual'nost' problemy obuslovlena nizkoy effektivnost'yu lecheniya i plohim prognozom mielofibroza do poslednego vremeni. Mielofibroz yavlyaetsya ugrozhayuschim zhizni zlokachestvennym novoobrazovaniem krovi s neblagopriyatnym prognozom i ogranichennym kolichestvom variantov lecheniya. Po rezul'tatam issledovaniy u bol'nyh mielofibrozom nablyudaetsya umen'shenie ozhidaemoy prodolzhitel'nosti zhizni s medianoy 5,7 let. Hotya allogennaya transplantaciya stvolovyh kletok mozhet privesti k izlecheniyu mielofibroza, dannaya procedura soprovozhdaetsya znachitel'noy chastotoy oslozhneniy i svyazannoy s ney smertnost'yu, takim obrazom, ee provedenie vozmozhno menee chem u 5 % bol'nyh molodogo vozrasta s horoshim sostoyaniem zdorov'ya. Poyavlenie novogo effektivnogo i bezopasnogo preparata dlya lecheniya mielofibroza Dzhakavi pozvolit dobit'sya luchshego kachestva zhizni i snizheniya simptomov u pacientov s dannoy patologiey. Cel'yu nashego issledovaniya stala ocenka effektivnosti ruksolitiniba u pacientov s diagnozami pervichnyy mielofibroz i post-policitemicheskiy mielofibroz, nahodivshihsya na lechenii v gematologicheskom otdelenii RKB im. N.A. Semashko. Poluchennye rezul'taty sootvetstvuyut dannym, poluchennym na bol'shih gruppah bol'nyh v issledovaniyah 3-y fazy COMFORT-I i COMFORT-II.
Aktual'nost' problemy obuslovlena nizkoy effektivnost'yu lecheniya i plohim prognozom mielofibroza do poslednego vremeni. Mielofibroz yavlyaetsya ugrozhayuschim zhizni zlokachestvennym novoobrazovaniem krovi s neblagopriyatnym prognozom i ogranichennym kolichestvom variantov lecheniya. Po rezul'tatam issledovaniy u bol'nyh mielofibrozom nablyudaetsya umen'shenie ozhidaemoy prodolzhitel'nosti zhizni s medianoy 5,7 let. Hotya allogennaya transplantaciya stvolovyh kletok mozhet privesti k izlecheniyu mielofibroza, dannaya procedura soprovozhdaetsya znachitel'noy chastotoy oslozhneniy i svyazannoy s ney smertnost'yu, takim obrazom, ee provedenie vozmozhno menee chem u 5 % bol'nyh molodogo vozrasta s horoshim sostoyaniem zdorov'ya. Poyavlenie novogo effektivnogo i bezopasnogo preparata dlya lecheniya mielofibroza Dzhakavi pozvolit dobit'sya luchshego kachestva zhizni i snizheniya simptomov u pacientov s dannoy patologiey. Cel'yu nashego issledovaniya stala ocenka effektivnosti ruksolitiniba u pacientov s diagnozami pervichnyy mielofibroz i post-policitemicheskiy mielofibroz, nahodivshihsya na lechenii v gematologicheskom otdelenii RKB im. N.A. Semashko. Poluchennye rezul'taty sootvetstvuyut dannym, poluchennym na bol'shih gruppah bol'nyh v issledovaniyah 3-y fazy COMFORT-I i COMFORT-II.
Keywords:
pervichnyy mielofibroz, mutaciya-JAK2, hMPZ, targetnaya terapiya
pervichnyy mielofibroz, mutaciya-JAK2, hMPZ, targetnaya terapiya
1. 2 Ochirova spislit
